A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy

被引:7
|
作者
Bastos, Ines M. [1 ,2 ]
Rebelo, Sandra [3 ]
Silva, Vera L. M. [1 ,2 ]
机构
[1] Univ Aveiro, LAQV REQUIMTE, P-3810193 Aveiro, Portugal
[2] Univ Aveiro, Dept Chem, P-3810193 Aveiro, Portugal
[3] Univ Aveiro, Dept Med Sci, Inst Biomed iBiMED, P-3810193 Aveiro, Portugal
关键词
Cancer; Poly(ADP-ribose) polymerase-1 (PARP1); Homologous Recombination; Inhibitor; Pyrazole; Indazole; BASE EXCISION-REPAIR; DNA-BINDING DOMAIN; HOMOLOGOUS RECOMBINATION; MAINTENANCE THERAPY; OVARIAN-CARCINOMA; END RESECTION; BREAK REPAIR; DOUBLE-BLIND; CELL-DEATH; POLYMERASE;
D O I
10.1016/j.bcp.2024.116045
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer is a disease with a high mortality rate characterized by uncontrolled proliferation of abnormal cells. The hallmarks of cancer evidence the acquired cells characteristics that promote the growth of malignant tumours, including genomic instability and mutations, the ability to evade cellular death and the capacity of sustaining proliferative signalization. Poly(ADP-ribose) polymerase-1 (PARP1) is a protein that plays key roles in cellular regulation, namely in DNA damage repair and cell survival. The inhibition of PARP1 promotes cellular death in cells with homologous recombination deficiency, and therefore, the interest in PARP protein has been rising as a target for anticancer therapies. There are already some PARP1 inhibitors approved by Food and Drug Administration (FDA), such as Olaparib and Niraparib. The last compound presents in its structure an indazole core. In fact, pyrazoles and indazoles have been raising interest due to their various medicinal properties, namely, anticancer activity. Derivatives of these compounds have been studied as inhibitors of PARP1 and presented promising results. Therefore, this review aims to address the importance of PARP1 in cell regulation and its role in cancer. Moreover, it intends to report a comprehensive literature review of PARP1 inhibitors, containing the pyrazole and indazole scaffolds, published in the last fifteen years, focusing on structure-activity relationship aspects, thus providing important insights for the design of novel and more effective PARP1 inhibitors.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors
    Rhee, Hee-Kyung
    Lim, So Yun
    Jung, Mi-Ja
    Kwon, Youngjoo
    Kim, Myung-Hwa
    Choo, Hea-Young Park
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (21) : 7537 - 7541
  • [42] Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors
    Skalitzky, DJ
    Marakovits, JT
    Maegley, KA
    Ekker, A
    Yu, XH
    Hostomsky, Z
    Webber, SE
    Eastman, BW
    Almassy, R
    Li, JK
    Curtin, NJ
    Newell, DR
    Calvert, AH
    Griffin, RJ
    Golding, BT
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (02) : 210 - 213
  • [43] Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
    Liu, Chia-Hao
    Chang, Yi
    Wang, Peng-Hui
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2017, 56 (05): : 713 - 714
  • [44] Poly (ADP-ribose) polymerase-1 (PARP) expression in triple-negative breast cancer
    Possanzini, P.
    Biasi, M. O.
    Fumagalli, C.
    Barberis, M.
    Barile, M.
    Bonanni, B.
    Viale, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1 (PARP1) INHIBITORS FOR THE TREATMENT OF SOLID TUMORS
    Priyancy, J.
    Bhumika, D. P.
    CONFERENCE ON DRUG DESIGN AND DISCOVERY TECHNOLOGIES, 2020, 355 : 31 - 35
  • [46] Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (Review)
    Wiggans, Alison J.
    Cass, Gemma K. S.
    Bryant, Andrew
    Lawrie, Theresa A.
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (02):
  • [47] The role of poly(ADP-ribose) polymerase-1 (PARP-1) in the cellular response to Topoisomerase I poisons
    Smith, L
    Willmore, E
    Hostomsky, Z
    Webber, SE
    Austin, CA
    Curtin, NJ
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S69 - S69
  • [48] Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases
    Ba, Xueqing
    Garg, Nisha Jain
    AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (03): : 946 - 955
  • [49] PARP-1 (Poly[ADP-Ribose] Polymerase-1): A Novel Target in Aortic Aneurysm
    Alves-Lopes, Rheure
    Touyz, Rhian M.
    HYPERTENSION, 2018, 72 (05) : 1087 - 1089
  • [50] Poly(ADP-ribose) polymerase-1 in the nervous system
    Ha, HC
    Snyder, SH
    NEUROBIOLOGY OF DISEASE, 2000, 7 (04) : 225 - 239